SCHEMBL18712866

SCHEMBL18712866

CCc1cnn(C2CN(C(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
NR1H2 P55055 1/20 0.41
USP30 Q70CQ3 1/20 0.39
RET P07949 1/20 0.39
NAMPT P43490 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PIK3CD O00329 1/20 0.37
SCN9A Q15858 1/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18172806 0.90 NR1H2 (0.44) GPR119DDB1CRBNNR1H2USP30
SCHEMBL21088324 0.83 DDB1 (0.42) GPR119DDB1CRBNNR1H2USP30
SCHEMBL18173277 0.83 GPR119 (0.47) GPR119DDB1CRBNNR1H2USP30
SCHEMBL25326690 0.83 DDB1 (0.43) GPR119DDB1CRBNNR1H2USP30
SCHEMBL11946807 0.83 DDB1 (0.43) GPR119DDB1CRBNNR1H2USP30
SCHEMBL985090 0.82 MPO (0.46) GPR119DDB1CRBNNR1H2USP30
SCHEMBL23511226 0.82 DDB1 (0.43) GPR119DDB1CRBNNR1H2USP30
SCHEMBL22585504 0.82 DDB1 (0.43) GPR119DDB1CRBNNR1H2USP30
SCHEMBL24990092 0.82 DDB1 (0.43) GPR119DDB1CRBNNR1H2USP30
SCHEMBL3598372 0.82 KDM5A (0.43) GPR119DDB1CRBNNR1H2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF GPR119 1664/4885DDB1 1045/4885CRBN 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.